Literature DB >> 20975003

Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.

Yoshinobu Onuma1, Patrick W Serruys, Laura E L Perkins, Takayuki Okamura, Nieves Gonzalo, Hector M García-García, Evelyn Regar, Marika Kamberi, Jennifer C Powers, Richard Rapoza, Heleen van Beusekom, Willem van der Giessen, Renu Virmani.   

Abstract

BACKGROUND: With the use of optical coherence tomography (OCT), alterations of the reflectance characteristics of everolimus-eluting bioresorbable vascular scaffold (BVS) struts have been reported in humans. In the absence of histology, the interpretation of the appearances of the struts by OCT remains speculative. We therefore report OCT findings with corresponding histology in the porcine coronary artery model immediately after and at 28 days and 2, 3, and 4 years after BVS implantation. METHODS AND
RESULTS: Thirty-five polymeric BVS (3.0×12.0 mm) were singly implanted in the main coronary arteries of 17 pigs that underwent OCT and were then euthanized immediately (n=2), at 28 days (n=2), at 2 years (n=3), at 3 years (n=5), or at 4 years (n=5) after implantation. All BVS-implanted arteries in these animals were evaluated by histology except for 5 arteries examined at 2 years with gel permeation chromatography to assess the biodegradation of the polymeric device. Fourteen arteries with BVS from an additional 6 pigs were examined by gel permeation chromatography at 1 (n=1), 1.5 (n=2), and 3 (n=2) years. Corresponding OCT and histology images were selected with the distal and proximal radiopaque markers used as landmarks. At 28 days, by OCT, 82% of struts showed sharply defined, bright reflection borders, best described as a box-shaped appearance. Histologically, all struts appeared intact with no evidence of resorption. At 2 years, by OCT, 60±20 struts were discernible per BVS with 80.4% of the strut sites as a box-shaped appearance. Despite their defined appearance by OCT, by histology, these structures appeared to be composed of proteoglycan, with polymeric material being at such low level as to be no longer quantifiable by chromatography. At 3 years, by OCT, recognizable struts decreased to 28±9 struts per BVS: 43.7% showed dissolved black box; 34.8%, dissolved bright box; 16.1%, open box; and 5.4%, preserved box appearance. Histology shows that connective tissue cells within a proteoglycan-rich matrix replaced the areas previously occupied by the polymeric struts and coalesced into the arterial wall. At 4 years, by OCT, 10±6 struts were recognizable as either dissolved black or dissolved bright box. In histology, these struts are minimally discernible as foci of low-cellular-density connective tissue. Relative to the prediction of histological type by OCT appearance, the preserved box appearance of OCT corresponds well with 2-year histology (86.4%), whereas the dissolved bright and black box appearances correspond to 3-year histology (88.0% and 90.7%, respectively). Struts indiscernible by OCT correspond to the integrated strut footprints seen at 4 years (100%).
CONCLUSIONS: Struts that are still discernible by OCT at 2 years are compatible with largely bioresorbed struts, as demonstrated by histological and gel permeation chromatography analysis. At 3 and 4 years, both OCT and histology confirm complete integration of the struts into the arterial wall.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20975003     DOI: 10.1161/CIRCULATIONAHA.109.921528

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  56 in total

1.  Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.

Authors:  Salvatore Brugaletta; Hector M Garcia-Garcia; Scot Garg; Josep Gomez-Lara; Roberto Diletti; Yoshinobu Onuma; Robert Jan van Geuns; Dougal McClean; Dariusz Dudek; Leif Thuesen; Bernard Chevalier; Stephan Windecker; Robert Whitbourn; Cecile Dorange; Karine Miquel-Hebert; Krishnankutty Sudhir; John A Ormiston; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2010-10-13       Impact factor: 2.357

2.  Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study.

Authors:  Michele Pighi; Fabrizio Tomai; Alessandro Petrolini; Leonardo de Luca; Giuseppe Tarantini; Alberto Barioli; Paola Colombo; Silvio Klugmann; Marco Ferlini; Maurizio Ferrario Ormezzano; Bruno Loi; Paolo Calabrò; Renato Maria Bianchi; Giuseppe Faggian; Alberto Forni; Corrado Vassanelli; Marco Valgimigli; Flavio Ribichini
Journal:  J Cardiovasc Transl Res       Date:  2015-12-18       Impact factor: 4.132

Review 3.  Emerging Technologies in Flow Diverters and Stents for Cerebrovascular Diseases.

Authors:  Michael Karsy; Jian Guan; Andrea A Brock; Anubhav Amin; Min S Park
Journal:  Curr Neurol Neurosci Rep       Date:  2017-10-28       Impact factor: 5.081

4.  Implications of a bioresorbable vascular scaffold implantation on vessel wall strain of the treated and the adjacent segments.

Authors:  Christos V Bourantas; Hector M Garcia-Garcia; Carlos A M Campos; Yao-Jun Zhang; Takashi Muramatsu; Marie-Angèle Morel; Shimpei Nakatani; Xingyu Gao; Yun-Kyeong Cho; Yuki Isibashi; Frank J H Gijsen; Yoshinobu Onuma; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-24       Impact factor: 2.357

5.  Challenging treatment of in-stent restenosis in a coronary bifurcation by implantation of a bioresorbable scaffold under optical coherence tomography guidance.

Authors:  Grzegorz Zuk; Dariusz Ciecwierz; Piotr Drewla; Marcin Gruchała; Juan Luis Gutiérrez-Chico; Milosz Jaguszewski
Journal:  Cardiol J       Date:  2019       Impact factor: 2.737

6.  Long-term clinical results of biodegradable vascular scaffold ABSORB BVS™ using the PSP-technique in patients with acute coronary syndrome.

Authors:  Jarosław Hiczkiewicz; Sylwia Iwańczyk; Aleksander Araszkiewicz; Magdalena Łanocha; Dariusz Hiczkiewicz; Stefan Grajek; Maciej Lesiak
Journal:  Cardiol J       Date:  2019-02-14       Impact factor: 2.737

7.  A head to head comparison of XINSORB bioresorbable sirolimus-eluting scaffold versus metallic sirolimus-eluting stent: 180 days follow-up in a porcine model.

Authors:  Li Shen; Yizhe Wu; Lei Ge; Yaojun Zhang; Qibing Wang; Juying Qian; Zhifen Qiu; Junbo Ge
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-21       Impact factor: 2.357

8.  Effect of strut distribution on neointimal coverage of everolimus-eluting bioresorbable scaffolds: an optical coherence tomography study.

Authors:  Takao Sato; John Jose; Abdelhakim Allai; Mohamed El-Mawardy; Ralph Tölg; Gert Richardt; Mohamed Abdel-Wahab
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

9.  Neointimal response to everolimus-eluting bioresorbable scaffolds implanted at bifurcating coronary segments: insights from optical coherence tomography.

Authors:  Takao Sato; John Jose; Mohamed El-Mawardy; Dmitriy S Sulimov; Ralph Tölg; Gert Richardt; Mohamed Abdel-Wahab
Journal:  Int J Cardiovasc Imaging       Date:  2016-10-18       Impact factor: 2.357

Review 10.  Clinical classification of plaque morphology in coronary disease.

Authors:  Fumiyuki Otsuka; Michael Joner; Francesco Prati; Renu Virmani; Jagat Narula
Journal:  Nat Rev Cardiol       Date:  2014-04-29       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.